Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective

[1]  P. Clifton,et al.  Practical Guidance for Food Consumption to Prevent Cardiovascular Disease. , 2020, Heart, lung & circulation.

[2]  Andrew B. Kirke,et al.  Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. , 2020, Heart, lung & circulation.

[3]  P. Clifton,et al.  Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry. , 2020, Heart, lung & circulation.

[4]  M. Banach,et al.  Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic , 2020, Pharmacological Research.

[5]  Laney K. Jones,et al.  Developing implementation strategies to improve uptake of guideline-recommended treatments for individuals with familial hypercholesterolemia: A protocol. , 2020, Research in social & administrative pharmacy : RSAP.

[6]  G. Kolovou,et al.  Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry. , 2020, Atherosclerosis.

[7]  S. Yamashita,et al.  Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care , 2020, Nature Reviews Cardiology.

[8]  C. Aguilar-Salinas,et al.  Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. , 2020, JAMA cardiology.

[9]  G. Watts,et al.  Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application. , 2019, Heart, lung & circulation.

[10]  T. A. Jacobson,et al.  National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. , 2019, Journal of clinical lipidology.

[11]  S. Humphries,et al.  Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care. , 2019, Atherosclerosis.

[12]  J. Kastelein,et al.  20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. , 2019, The New England journal of medicine.

[13]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. , 2019, Circulation.

[14]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[15]  K. Nasir,et al.  Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy. , 2019, JACC Cardiovascular Imaging.

[16]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[17]  A. Searle,et al.  Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis , 2019, BMJ Open.

[18]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[19]  Jeffrey Braithwaite,et al.  The time has come: Embedded implementation research for health care improvement. , 2019, Journal of evaluation in clinical practice.

[20]  M. Koschinsky,et al.  Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. , 2022, Journal of clinical lipidology.

[21]  J. Steinberger,et al.  Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. , 2019, Circulation.

[22]  Odyssey Outcomes Investigators.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .

[23]  G. Watts,et al.  Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part. , 2018, Atherosclerosis.

[24]  F. Raal,et al.  Familial hypercholesterolemia treatments: Guidelines and new therapies. , 2018, Atherosclerosis.

[25]  D. Ledbetter,et al.  Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. , 2018, Journal of the American College of Cardiology.

[26]  G. Watts,et al.  Parent–child genetic testing for familial hypercholesterolaemia in an Australian context , 2018, Journal of paediatrics and child health.

[27]  L. Pérez de Isla,et al.  Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study. , 2018, Journal of clinical lipidology.

[28]  G. Watts,et al.  The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats , 2018, Current Atherosclerosis Reports.

[29]  F. Raal,et al.  Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol , 2018, European heart journal.

[30]  H. Whitaker,et al.  Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland , 2018, European Respiratory Journal.

[31]  M. Banach,et al.  Optimizing Cholesterol Treatment in Patients With Muscle Complaints. , 2017, Journal of the American College of Cardiology.

[32]  D. Gaudet,et al.  Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. , 2017, Journal of the American College of Cardiology.

[33]  G. Watts,et al.  Knowns and unknowns in the care of pediatric familial hypercholesterolemia , 2017, Journal of Lipid Research.

[34]  G. Watts,et al.  Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs. , 2017, Journal of clinical lipidology.

[35]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[36]  G. Watts,et al.  Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study) , 2017, Circulation.

[37]  C. Shoulders,et al.  HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. , 2016, Atherosclerosis.

[38]  D. Wald,et al.  Child-Parent Familial Hypercholesterolemia Screening in Primary Care. , 2016, The New England journal of medicine.

[39]  Brian A Ference,et al.  Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. , 2016, JAMA.

[40]  Raymond Dalgleish,et al.  HGVS Recommendations for the Description of Sequence Variants: 2016 Update , 2016, Human mutation.

[41]  Matthew K Ito,et al.  The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. , 2015, Circulation.

[42]  N. Bratina,et al.  Universal Screening for Familial Hypercholesterolemia in Children. , 2015, Journal of the American College of Cardiology.

[43]  J. Borén,et al.  Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment , 2015, European heart journal.

[44]  Yu Kataoka,et al.  Impact of statins on serial coronary calcification during atheroma progression and regression. , 2015, Journal of the American College of Cardiology.

[45]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[46]  Z. Ademi,et al.  Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. , 2014, Journal of clinical lipidology.

[47]  J. Emery,et al.  Familial hypercholesterolaemia: a model of care for Australasia. , 2011, Atherosclerosis. Supplements.

[48]  S. Humphries,et al.  Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing , 2008, Clinical chemistry and laboratory medicine.

[49]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[50]  J. Kastelein,et al.  Carotid Intima-Media Thickness in Children With Familial Hypercholesterolemia , 2014, Circulation research.

[51]  THE ROYAL AUSTRALIAN COLLEGE OF GENERAL PRACTITIONERS , 1974 .

[52]  J. Lumley.  AUSTRALIA , 1920, The Lancet.

[53]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.